# MINOVA PHARMA

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/minova-pharma

- Industry: Pharmaceuticals
- Headquarters: Nanjing, China
- Website: www.minovapharma.com
- Total disclosed funding: $29M
- Latest round: Series B (Aug 25, 2025)
- Investors on record: 6

## About

Established in 2021 and based in Nanjing, China, MINOVA PHARMA operates as a pharmaceutical developer that focuses on the field of mental and medical beauty. The company's founder, Fei Liu, worked in Jiangsu Simcere Pharmaceutical Co.,Ltd., then established Nanjing Simnovtec pharmaceutical. It was recognized as Nanjing Jiangbei New District Science and Technology Laboratory and Jiangsu Private Science and Technology Enterprise. As of July 2022, the company raised four rounds, and the series A round funding reached over CNY 100 million. In January 2024, MINOVA PHARMA raised a pre-series B funding for CNY 100 million. In August 2025, MINOVA PHARMA raised CNY 100 million in series B funding led by new investor IDG Capital with participation from returning investor Oriza Holdings. MINOVA PHARMA focuses on the R&D of mental illness drugs, and medical beauty drugs. The company is equipped with more than 200 sets of R&D equipments, and has a platform for phenotype-based drug screening for disfiguring diseases, a platform for small molecule total synthesis, a platform for evaluation of durability, and a platform for novel drug delivery systems. It has 6 product lines which can be used in curing depression, hair loss, acne, photodamage, various kinds of pigmentation, scarring, abnormal accumulation of localized fat, and other disorders in the field of mental and cosmetic. The company generates revenue through providing the R&D of mental illness drugs, and medical beauty drugs. The company will focus on accelerating the advancement of the innovative drug R&D pipeline, as well as the market promotion and sales layout of its core product "Rongzhi®" lipolysis injection, injecting strong momentum into the company's continued leadership in drug R&D in the consumer healthcare field.

## Funding rounds

- Series B, Aug 25, 2025, $14M — IDG Capital, Oriza Holdings
- Series A, Jul 21, 2022, $15M — GP Capital, Oriza Holdings, Huagai Capital, Lyzz Capital, Wenzhou Investment

## Investors

- GP Capital (https://capitalatlas.ai/funds/gp-capital) — Series A
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series A, Series B
- Huagai Capital (https://capitalatlas.ai/funds/huagai-capital) — Series A
- Lyzz Capital (https://capitalatlas.ai/funds/lyzz-capital) — Series A
- Wenzhou Investment (https://capitalatlas.ai/funds/wenzhou-investment) — Series A
- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Series B